RG1-VLP and other L2-based, broad-spectrum HPV vaccine candidates

B Huber, JW Wang, RBS Roden… - Journal of Clinical …, 2021 - mdpi.com
Licensed human papillomavirus (HPV) vaccines contain virus-like particles (VLPs) self-
assembled from L1 major-capsid proteins that are remarkably effective prophylactic …

Progress in L2-based prophylactic vaccine development for protection against diverse human papillomavirus genotypes and associated diseases

P Olczak, RBS Roden - Vaccines, 2020 - mdpi.com
The human papillomaviruses (HPVs) are a family of small DNA tumor viruses including over
200 genotypes classified by phylogeny into several genera. Different genera of HPVs cause …

Chimeric L2-based virus-like particle (VLP) vaccines targeting cutaneous human papillomaviruses (HPV)

B Huber, C Schellenbacher, S Shafti-Keramat… - PLoS …, 2017 - journals.plos.org
Common cutaneous human papillomavirus (HPV) types induce skin warts, whereas species
beta HPV are implicated, together with UV-radiation, in the development of non-melanoma …

[HTML][HTML] Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses

C Schellenbacher, K Kwak, D Fink… - Journal of Investigative …, 2013 - Elsevier
Licensed human papillomavirus (HPV) vaccines, based on virus-like particles (VLPs) self-
assembled from major capsid protein L1, afford type-restricted protection against HPV types …

Virus-like particle-based L2 vaccines against HPVs: where are we today?

R Yadav, L Zhai, E Tumban - Viruses, 2019 - mdpi.com
Human papillomaviruses (HPVs) are the most common sexually transmitted infections
worldwide. Ninety percent of infected individuals clear the infection within two years; …

Developments in L2-based human papillomavirus (HPV) vaccines

C Schellenbacher, RBS Roden, R Kirnbauer - Virus research, 2017 - Elsevier
Infections with sexually transmitted high-risk Human Papillomavirus (hrHPV), of which there
are at least 15 genotypes, are responsible for a tremendous disease burden by causing …

Progress and prospects for L2-based human papillomavirus vaccines

RT Jiang, C Schellenbacher, B Chackerian… - Expert review of …, 2016 - Taylor & Francis
Human papillomavirus (HPV) is a worldwide public health problem, particularly in resource-
limited countries. Fifteen high-risk genital HPV types are sexually transmitted and cause 5 …

RG2-VLP: a vaccine designed to broadly protect against anogenital and skin human papillomaviruses causing human cancer

P Olczak, K Matsui, M Wong, J Alvarez… - Journal of …, 2022 - Am Soc Microbiol
The family of human papillomaviruses (HPV) includes over 400 genotypes. Genus α
genotypes generally infect the anogenital mucosa, and a subset of these HPV are a …

Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines

C Schellenbacher, R Roden, R Kirnbauer - Journal of virology, 2009 - Am Soc Microbiol
The amino (N) terminus of the human papillomavirus (HPV) minor capsid protein L2 can
induce low-titer, cross-neutralizing antibodies. The aim of this study was to improve …

Emerging human papillomavirus vaccines

B Ma, B Maraj, NP Tran, J Knoff, A Chen… - Expert opinion on …, 2012 - Taylor & Francis
Introduction: Identification of human papillomavirus (HPV) as the etiologic factor of cervical,
anogenital, and a subset of head and neck cancers has stimulated the development of …